162 related articles for article (PubMed ID: 16626808)
1. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Quinn LP; Stean TO; Chapman H; Brown M; Vidgeon-Hart M; Upton N; Billinton A; Virley DJ
J Neurosci Methods; 2006 Sep; 156(1-2):218-27. PubMed ID: 16626808
[TBL] [Abstract][Full Text] [Related]
2. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ
J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809
[TBL] [Abstract][Full Text] [Related]
3. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
4. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
[TBL] [Abstract][Full Text] [Related]
5. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
6. Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice.
Leng A; Yee BK; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):449-56. PubMed ID: 15313033
[TBL] [Abstract][Full Text] [Related]
7. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.
Hirst SJ; Ferger B
Synapse; 2008 Feb; 62(2):85-90. PubMed ID: 17992685
[TBL] [Abstract][Full Text] [Related]
8. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
[TBL] [Abstract][Full Text] [Related]
9. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
10. [The effect of haloperidol at a low dose on the development of experimental parkinsonian syndrome].
Korshunov AM; Voronina TA; Churiukanov VV; Iakhno NN
Eksp Klin Farmakol; 1995; 58(6):7-9. PubMed ID: 8704620
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
Li X; Matsumoto K; Murakami Y; Tezuka Y; Wu Y; Kadota S
Pharmacol Biochem Behav; 2005 Oct; 82(2):345-52. PubMed ID: 16214209
[TBL] [Abstract][Full Text] [Related]
13. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
Yarkov AV; Hanger D; Reploge M; Joyce JN
Pharmacol Biochem Behav; 2003 Dec; 76(3-4):551-62. PubMed ID: 14643855
[TBL] [Abstract][Full Text] [Related]
14. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice.
Hong Z; Wang G; Gu J; Pan J; Bai L; Zhang S; Chen SD
Eur J Neurosci; 2007 Sep; 26(6):1500-8. PubMed ID: 17714494
[TBL] [Abstract][Full Text] [Related]
15. Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
Luchtman DW; Shao D; Song C
Physiol Behav; 2009 Aug; 98(1-2):130-8. PubMed ID: 19410592
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Teng X; Sakai T; Liu L; Sakai R; Kaji R; Fukui K
J Neurochem; 2006 May; 97(4):1126-35. PubMed ID: 16686692
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease.
Grealish S; Mattsson B; Draxler P; Björklund A
Eur J Neurosci; 2010 Jun; 31(12):2266-78. PubMed ID: 20529122
[TBL] [Abstract][Full Text] [Related]
19. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection.
Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J
J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
